Department of Stem Cell and Regenerative Biotechnology, Humanized Pig Research Center (SRC), Konkuk University, Seoul, Republic of Korea.
Department of Emergency Medicine, College of Medicine, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, United States.
Life Sci. 2019 Jul 15;229:233-250. doi: 10.1016/j.lfs.2019.05.012. Epub 2019 May 17.
Cardiovascular disease (CVD) is among the leading causes of mortality worldwide. The shortage of donor hearts to treat end-stage heart failure patients is a critical problem. An average of 3500 heart transplant surgeries are performed globally, half of these transplants are performed in the US alone. Stem cell therapy is growing rapidly as an alternative strategy to repair or replace the damaged heart tissue after a myocardial infarction (MI). Nevertheless, the relatively poor survival of the stem cells in the ischemic heart is a major challenge to the therapeutic efficacy of stem-cell transplantation. Recent advancements in tissue engineering offer novel biomaterials and innovative technologies to improve upon the survival of stem cells as well as to repair the damaged heart tissue following a myocardial infarction (MI). However, there are several limitations in tissue engineering technologies to develop a fully functional, beating cardiac tissue. Therefore, the main goal of this review article is to address the current advancements and barriers in cardiac tissue engineering to augment the survival and retention of stem cells in the ischemic heart.
心血管疾病 (CVD) 是全球主要的死亡原因之一。用于治疗晚期心力衰竭患者的供体心脏短缺是一个关键问题。全球平均每年进行 3500 例心脏移植手术,其中一半仅在美国进行。干细胞疗法作为一种替代策略,在心肌梗死后修复或替换受损的心脏组织方面发展迅速。然而,干细胞在缺血性心脏中的相对较差的存活率是干细胞移植治疗效果的主要挑战。组织工程的最新进展为改善干细胞的存活率以及修复心肌梗死后受损的心脏组织提供了新型生物材料和创新技术。然而,在组织工程技术中,要开发出具有完全功能和跳动能力的心脏组织,仍存在一些局限性。因此,本文的主要目标是解决心脏组织工程中目前的进展和障碍,以提高缺血性心脏中干细胞的存活率和保留率。